OMAHA-003: what clinicians are saying

Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

Screened window

Mar 1, 2024 → Nov 6, 2026

Cited window

Apr 30, 2025 → Oct 23, 2026

Retrieved

Nov 14, 2026

Title

A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)

Registry

NCT06136624

Study IDs

5684-003 · 2023-504899-25-00 (EU CT) · MK-5684-003 (MSD) · jRCT2031240029 (Japan Registry of Clinical Trials (jRCT)) · U1111-1287-5304 (UTN)

Sponsor

Merck Sharp & Dohme LLC

Design

Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

1,310 estimated

Registered

2023-11-18

Start

2023-12-31 actual

Primary completion

2028-11-30 estimated

Primary endpoints

• Overall Survival (OS) in Androgen Receptor Ligand Binding Domain (AR LBD) Mutation-Positive Participants
• OS in AR LBD Mutation-Negative Participants

Interventions

7 registered

More on: Prostate cancer

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a view on efficacy and toxicity of adding mevrometostat to enzalutamide after abiraterone in metastatic castration-resistant prostate cancer.
• –6 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: 23 sources about other trials or topics are not included.
• –The sources reviewed for this edition are not a representative sample of HCP opinion. Reposts, organizational relays and repeated posts by one account must not be counted as additional independent clinical assessments.

How reports are built and checked: Methods.

Last checked for new commentary Nov 14, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "OMAHA-003" (NCT06136624), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "omaha-003-nct06136624". If you cannot make requests, read https://www.erudio.com/reports/omaha-003-nct06136624.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT06136624", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT06136624 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/omaha-003-nct06136624.json
curl https://www.erudio.com/reports/omaha-003-nct06136624.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "omaha-003-nct06136624" })